- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03646747
Oxygen Enhanced MRI Measurement in Head and Neck Cancer: Validation and Efficacy of Response.
Study Overview
Detailed Description
This is a prospective pilot study funded by the NIHR. Healthy participants and patients will be recruited in The Christie NHS Foundation Trust and will be asked to undergo oxygen-enhanced magnetic resonance imaging (OE-MRI) and dynamic contrast-enhanced MRI (DCE-MRI). This study builds on the work recently been completed in lung cancer. Clinical data will be collected from patients notes.
Tumour hypoxia is common in solid tumours and associated with poor response to radiotherapy, poor loco-regional control and survival outcomes in head and neck cancer. There is a need to develop non-invasive tests that can measure tumour hypoxia to improve radiotherapy for these patients. The study will involve 3 components:
Reproducibility and feasibility: The reproducibility of OE-MRI in head and neck cancer is unknown. Ten healthy participants will be asked to undergo two baseline OE-MRI scans with either nasal cannula or facial mask to breathe air and oxygen throughout. The order of which non-invasive breathing method will be used first will be randomized.
Following this initial pilot OE-MRI will be tested in 30 patients with solid head and neck tumours. To assess reproducibility in patients 2 OE-MRI will be performed at baseline.
- Effect of radiotherapy on tumour and normal tissue: OE-MRI and DCE-MRI signals will be measured at baseline before standard radiotherapy treatment begins and at the end of week 2 week and week 4 following the start of radiotherapy. Comparison of hypoxia measurements will be taken.
- Biological validation: All 30 patients will undergo a diagnostic biopsy as standard of care at their local hospital. Tissue samples will be requested and multi-gene hypoxia signatures will be tested. OE-MRI signals will be compared with tissue sample from the same patient and the presence of changes in tumour known to be associated with hypoxia will be analysed.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sally Falk
- Phone Number: 8318 0044 161 446 8318
- Email: sally.falk@christie.nhs.uk
Study Contact Backup
- Name: Christina Hague
- Phone Number: 8318 0044 161 446 8318
- Email: christina.hague@christie.nhs.uk
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18 or over
- Able to receive and understand verbal and written information regarding the study and given written informed consent
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Adequate renal function: Calculated creatinine clearance (Cockcroft-Gault) ≥30mL/min
- Be able to lie comfortably on back for up to 1 hour
- Be able to tolerate a thermoplastic shell
Female patients must meet one of the following criteria:
i. Postmenopausal for a minimum of one year ii. Surgically sterile iii. Not pregnant, confirmed by B-HCG blood test. iv. Not breastfeeding
- Cohort A (healthy participants): Up to 10 will be recruited to validate the use of nasal cannula
- Cohort B (patients): Any patient with HNSCC who is due to start definitive radiotherapy +/- chemotherapy. Up to 30 will be recruited. Each patient prior to recruitment will undergo a diagnostic biopsy at their local hospital as standard of care. The formalin fixed paraffin embedded (FFPE) tumour biopsy sample blocks will be requested from each site and stored in the Manchester Cancer Research Centre (MRCR) and tested for a multi-gene signature.
Exclusion Criteria:
Healthy volunteers or patients with any contraindications to MRI scanning (i.e heart valve replacement, pacemaker, metal implants not approved for MRI, neurostimulators), history of contrast (Gadolinium) allergy or pregnancy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: MRI scan
10 healthy participants will be asked to undergo two baseline OE-MRI scans with either nasal cannula or facial mask to breathe air and oxygen throughout. Following this initial pilot, OE-MRI will be tested in 30 patients with solid head and neck tumours. |
Additional imaging using MRI scan
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of hypoxia in head and neck squamous cell cancer using oxygen enhanced Magnetic resonance imaging (using a range of different MR sequences)
Time Frame: 3 years
|
Assessment of hypoxia in head and neck squamous cell cancer using oxygen enhanced Magnetic resonance imaging (using a range of different MR sequences)
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Optimal MRI sequence to image participants with head and neck cancer, based on tumour and organ at risk visualisation.
Time Frame: 3 years
|
Optimal MRI sequence to image participants with head and neck cancer, based on tumour and organ at risk visualisation.
|
3 years
|
Treatment response in a number of participants with head and neck cancer treated with radiotherapy +/- systemic therapy
Time Frame: 3 years
|
Treatment response in a number of participants with head and neck cancer treated with radiotherapy +/- systemic therapy
|
3 years
|
Treatment related toxicities in a number of participants with head and neck cancer as assessed during and after treatment completion
Time Frame: 3 years
|
Treatment related toxicities in a number of participants with head and neck cancer as assessed during and after treatment completion
|
3 years
|
Survival outcomes in a number of participants treated with radiotherapy +/- systemic therapy for head and neck cancer
Time Frame: 3 years
|
Survival outcomes in a number of participants treated with radiotherapy +/- systemic therapy for head and neck cancer
|
3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: James O'Connor, University of Manchester
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18_RADIO_133
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Cancer
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Mayo ClinicRecruitingCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedHead And Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
Radboud University Medical CenterUnknown
-
Centre Oscar LambretUnknownEpidermoid Head and Neck CancerFrance
Clinical Trials on MRI scan
-
University of ChicagoRecruitingBreast CancerUnited States
-
Jeffrey A. Lieberman, MDTerminated
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH)TerminatedSchizophreniaUnited States
-
The Clatterbridge Cancer Centre NHS Foundation...Unknown
-
University of LeicesterNational Institute for Health Research, United KingdomCompletedPatients With Heart Failure and Preserved Ejection Fraction - HFpEF | Patients With Heart Failure With Reduced Ejection Fraction - HFrEF | Healthy Controls Group - Age and Sex-matched
-
Radboud University Medical CenterCompletedHead and Neck NeoplasmsNetherlands
-
University Hospitals Bristol and Weston NHS Foundation...Bosum Buddies; Friends of the Bristol Haematology and Oncology CentreTerminated
-
M.D. Anderson Cancer CenterNot yet recruitingBrain Malignancies | PseudoprogressionUnited States
-
University College London HospitalsRecruitingArthritis, Juvenile Idiopathic | Enthesitis-Related Arthritis, JuvenileUnited Kingdom
-
Amsterdam UMC, location VUmcMRIguidance B.V.CompletedSinusitis | Hearing Loss | Head and Neck Tumor | Cholesteatoma | Imaging of Bony Structures of the Head (Various Conditions)Netherlands